Daniel Katzman Email & Phone Number

At Unleash, I lead our mission to revolutionize cancer treatment through our pioneering oncolytic virus platform. Steering the strategic direction and innovation, I oversee our efforts to develop and commercialize next-generation therapies that target the tumor microenvironment for more effective and less invasive cancer care. Under my leadership, we have successfully advanced our lead product, UIO-524, into clinical testing for bladder cancer, secured significant fundraising, and built a robust intellectual property portfolio. Our focus on developing treatments that address unmet needs in cancer care drives our team towards delivering transformative outcomes for patients worldwide.

Actively engaged in the foundational stages of the company, providing strategic guidance on business development and fundraising initiatives. My role has been instrumental in shaping the company’s vision and ensuring the alignment of our growth strategies with industry standards and investor expectations.

Precision Virologics’ biologically targeted adenovirus vaccines provide a new approach to the expanding threat of emerging infectious diseases. Emerging infectious diseases represent a grave threat to global health, agriculture and the economy. Zika infection continues to be a national healthcare priority. The markets for Zika vaccines is estimated at well over one billion dollars. The NIH and pharma companies rushed to the clinic with sub-optimal vaccines for Zika. Particularly they share a potentially fatal flaw related to the cross-reactivity with Dengue, which may limit their potential to get approved. The cross-reactivity of existing Zika vaccines may leave vaccinated individuals subject to a significantly more severe reaction to Dengue. Precision’s technology embodies critical advantages over competitors both in terms of potency and lack of cross-reactivity with Dengue.

Rio De Janeiro, Br

Msc, Biochemistry

Bachiller